Podcast of business and financial stories, Behind the Money

Behind the Money

Podcast of business and financial stories

From hostile takeovers to C-suite intrigue, Behind the Money takes you inside the business and financial stories of the moment with reporting from Financial Times journalists around the world.

Equity Bottom-Up

<ul>
<li>Pfizer and Novo Nordisk engaged in a heated battle for control over biotech company Metcera, which is developing innovative weight loss drugs</li>
<li>Novo Nordisk, once seen as a leader in the obesity drug market, has recently faced challenges and a decline in stock price due to competition from Eli Lilly and a weaker drug pipeline</li>
<li>Investors are closely watching the outcome of the bidding war between Pfizer and Novo Nordisk, as the future of the weight loss drug market could be lucrative and competitive</li>
</ul>
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Pfizer and Novo Nordisk engaged in a heated battle for control over biotech company Metcera, which is developing innovative weight loss drugs
Novo Nordisk, once seen as a leader in the obesity drug market, has recently faced challenges and a decline in stock price due to competition from Eli Lilly and a weaker drug pipeline
Investors are closely watching the outcome of the bidding war between Pfizer and Novo Nordisk, as the future of the weight loss drug market could be lucrative and competitive

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Thematic (Sector/Industry)

<ul><li>Westport in County Meal, Ireland is a lively town with traditional pubs and a scenic backdrop of Croagh Patrick mountain.</li><li>The town benefits from American pharmaceutical companies like Allergan manufacturing products such as Botox, thanks to Ireland's low corporate tax rates.</li><li>However, President Trump's desire to bring back manufacturing to the US poses a threat to Ireland's economy and its relationship with multinational companies.</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Westport in County Meal, Ireland is a lively town with traditional pubs and a scenic backdrop of Croagh Patrick mountain.The town benefits from American pharmaceutical companies like Allergan manufacturing products such as Botox, thanks to Ireland's low corporate tax rates.However, President Trump's desire to bring back manufacturing to the US poses a threat to Ireland's economy and its relationship with multinational companies.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

How Trump’s tariffs threaten Ireland’s pharma fortune

<ul><li>Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaign</li><li>Pfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sector</li><li>Pfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investor</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Pfizer CEO Albert Borla receives a strange email from the company's former CFO Frank D'Amelio, signaling the beginning of a chaotic activist investor campaignPfizer's success with the Covid-19 vaccine leads to record highs in market cap, but challenges arise as the vaccine becomes old news and competitors emerge in the weight loss drug sectorPfizer's acquisition of cancer drug maker CGenta for $43 billion is criticized by investors, leading to a collapse in the company's share price and making it a prime target for an activist investorThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

An activist tried to take on Pfizer. Then things got messy

United States

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals.  The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer Inc (PFE US)

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

The battle between Pfizer and Novo Nordisk for biotech company Metcera highlights the fierce competition and high stakes in the lucrative weight...

Behind the Money

How Trump’s tariffs threaten Ireland’s pharma fortune

Westport, County Mayo in Ireland, known for traditional bars and lively atmosphere, faces uncertainty as President Trump's threats to bring...

Behind the Money

An activist tried to take on Pfizer. Then things got messy

Pfizer, a pharmaceutical giant, faces challenges post-pandemic including a failed acquisition and investor doubts about its future growth potential.

Behind the Money

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)